CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Alumis’ TYK2 drug fails in key lupus study

Data ReadoutnegativeNegative
AI Analysis

Summary

Alumis' TYK2 inhibitor failed in a key lupus study, adding to challenges for the TYK2 blocker class outside of psoriasis and psoriatic arthritis indications.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

TYK2 drug failed in key lupus study

Importance:6/10
Sentiment:
-0.80
lupusTYK2clinical trial failureimmunology

Read the original article

Published by BioPharma Dive on September 1, 2026 3:28 PM

Read Original